NKTR vs. BRK-B

Last updated Apr 2, 2026

Compare and contrast key facts about Nektar Therapeutics (NKTR) and Berkshire Hathaway Inc. (BRK-B).

Performance

NKTR vs. BRK-B - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nektar Therapeutics (NKTR) and Berkshire Hathaway Inc. (BRK-B). The values are adjusted to include any dividend payments, if applicable.

NKTR vs. BRK-B - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NKTR Nektar Therapeutics	79.07%	203.08%	64.60%	-75.00%	-83.27%	-20.53%	-21.26%	-34.32%	-44.96%	386.72%
BRK-B Berkshire Hathaway Inc.	-4.80%	10.89%	27.09%	15.46%	3.31%	28.95%	2.37%	10.93%	3.01%	21.62%

Fundamentals

Market Cap NKTR : $1.54B BRK-B : $1.03T
EPS NKTR : -$10.15 BRK-B : $31.03
PS Ratio NKTR : 22.15 BRK-B : 2.78
PB Ratio NKTR : 17.11 BRK-B : 1.44
Total Revenue (TTM) NKTR : $55.23M BRK-B : $371.37B
Gross Profit (TTM) NKTR : $55.04M BRK-B : $116.89B
EBITDA (TTM) NKTR : -$122.97M BRK-B : $87.30B

Returns By Period

In the year-to-date period, NKTR achieves a 79.07% return, which is significantly higher than BRK-B's -4.80% return. Over the past 10 years, NKTR has underperformed BRK-B with an annualized return of -9.98%, while BRK-B has yielded a comparatively higher 12.78% annualized return.

NKTR

• 1D: 5.23%
• 1M: 10.75%
• YTD: 79.07%
• 6M: 28.65%
• 1Y: 691.99%
• 3Y*: 92.93%
• 5Y*: -24.37%
• 10Y*: -9.98%

BRK-B

• 1D: -0.15%
• 1M: -0.35%
• YTD: -4.80%
• 6M: -3.95%
• 1Y: -10.22%
• 3Y*: 15.72%
• 5Y*: 13.13%
• 10Y*: 12.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NKTR vs. BRK-B — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NKTR

NKTR Risk / Return Rank: 99
NKTR Sharpe Ratio Rank: 98
NKTR Sortino Ratio Rank: 99
NKTR Omega Ratio Rank: 98
NKTR Calmar Ratio Rank: 99
NKTR Martin Ratio Rank: 99

BRK-B

BRK-B Risk / Return Rank: 17
BRK-B Sharpe Ratio Rank: 16
BRK-B Sortino Ratio Rank: 16
BRK-B Omega Ratio Rank: 16
BRK-B Calmar Ratio Rank: 17
BRK-B Martin Ratio Rank: 19

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NKTR vs. BRK-B - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NKTR	BRK-B	Difference
Sharpe ratio Return per unit of total volatility	3.69	-0.56	+4.25
Sortino ratio Return per unit of downside risk	5.91	-0.65	+6.56
Omega ratio Gain probability vs. loss probability	1.67	0.91	+0.76
Calmar ratio Return relative to maximum drawdown	13.80	-0.68	+14.48
Martin ratio Return relative to average drawdown	33.65	-1.16	+34.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NKTR vs. BRK-B - Sharpe Ratio Comparison

The current NKTR Sharpe Ratio is 3.69, which is higher than the BRK-B Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of NKTR and BRK-B, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NKTR	BRK-B	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.69	-0.56	+4.25
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.20	0.77	-0.97
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.10	0.66	-0.76
Sharpe Ratio (All Time) Calculated using the full available price history	0.01	0.48	-0.47

Correlation

The correlation between NKTR and BRK-B is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NKTR vs. BRK-B - Dividend Comparison

Neither NKTR nor BRK-B has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NKTR vs. BRK-B - Drawdown Comparison

The maximum NKTR drawdown since its inception was -99.61%, which is greater than BRK-B's maximum drawdown of -53.86%. Use the drawdown chart below to compare losses from any high point for NKTR and BRK-B.

Drawdown Indicators

	NKTR	BRK-B	Difference
Max Drawdown Largest peak-to-trough decline	-99.61%	-53.86%	-45.75%
Max Drawdown (1Y) Largest decline over 1 year	-46.54%	-14.95%	-31.59%
Max Drawdown (5Y) Largest decline over 5 years	-97.93%	-26.58%	-71.35%
Max Drawdown (10Y) Largest decline over 10 years	-99.61%	-29.57%	-70.04%
Current Drawdown Current decline from peak	-95.35%	-11.36%	-83.99%
Average Drawdown Average peak-to-trough decline	-68.17%	-11.07%	-57.10%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.09%	8.72%	+10.37%

Volatility

NKTR vs. BRK-B - Volatility Comparison

Nektar Therapeutics (NKTR) has a higher volatility of 17.64% compared to Berkshire Hathaway Inc. (BRK-B) at 4.33%. This indicates that NKTR's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NKTR	BRK-B	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.64%	4.33%	+13.31%
Volatility (6M) Calculated over the trailing 6-month period	65.68%	11.14%	+54.54%
Volatility (1Y) Calculated over the trailing 1-year period	189.39%	18.30%	+171.09%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	121.48%	17.20%	+104.28%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.96%	19.45%	+77.51%

Financials